CHO-H01
- Generic Name
- CHO-H01
A Study to Assess Safety and Efficacy of CHO-H01 As a Single Agent/Combined with Lenalidomide in Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 1
Recruiting
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Cho Pharma Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05950165
- Locations
- 🇨🇳
China Medical University Hospital - Hematology/Oncology - Taichung, Taichung City, Taiwan
🇨🇳National Cheng Kung University Hospital - Internal Medicine, Tainan, Taiwan
🇨🇳National Taiwan University Hospital - Hematology And Oncology, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath